User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

3914

Interactions with Platform & by Email *

INTERACTIONS

705

Unique # Participated *

PARTICIPANTS

117

Responses Validated *

VALIDATIONS

34

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Market Snapshots.....II-1
Market Drivers.....II-1
Market Restraints.....II-1
Major Players.....II-1
1$120
   Increasing Prevalence of Multiple Sclerosis.....II-2 1$120
   Table 1: World Multiple Sclerosis Prevalence in Thousands by Select Countries for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-31$350
   Table 2: Prevalence by Types of Multiple Sclerosis (includes corresponding Graph/Chart).....II-4
MS Therapeutics in the Market.....II-4
Key Multiple Sclerosis Drugs.....II-4
1$350
   Interferon Drugs.....II-5
Beta Interferon Drugs in Multiple Sclerosis Treatment.....II-5
Non-Interferon Drugs.....II-5
1$120
   Non-Interferon Drugs in Multiple Sclerosis Treatment.....II-6
High Unmet Need and Rich Pipeline to Expand MS Market.....II-6
Challenges Ahead.....II-6
1$120
   Interferon-based Drugs Dominate Multiple Sclerosis Market.....II-7
Sales Dip Inevitable for Current Therapies.....II-7
1$120
   Tough Times Ahead for Betaseron.....II-8
Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies.....II-8
1$120
   Competitive Landscape.....II-9
Table 3: Global Multiple Sclerosis Market by Leading Drugs (2008 & 2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart).....II-9
2$350
   Recent Clinical Trial Activity – An Overview.....II-111$120
   Drugs Under Development for Treating Multiple Sclerosis.....II-121$120
   FTY 720 (Fingolimod).....II-13
Mylinax.....II-13
Laquinimod.....II-13
1$120
   Alemtuzumab.....II-14
Teriflunomide.....II-14
BG-12 (Oral Fumarate).....II-14
1$120
   MN-166.....II-15
Rituxan/MabThera (Rituximab).....II-15
1$120
   Vaccines for Multiple Sclerosis.....II-161$120
   Definition.....II-17
Causes of Multiple Sclerosis.....II-17
Different Forms of Multiple Sclerosis.....II-17
1$120
   Pathology.....II-181$120
   Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat Multiple
  Sclerosis.....II-19
Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA.....II-19
Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of
  MS.....II-19
1$120
   Novartis Obtains FDA Approval for Extavia.....II-20
Merck Serono Collaborates with Brigham and Women's Hospital to Extend Multiple
  Sclerosis Research.....II-20
Merck Serono Announces Encouraging Phase III Results of Oral Mylinax.....II-20
Merck Serono Acquires Rights to Apitope’s Multiple Sclerosis Approach.....II-20
1$120
   Teva and Active Biotech Obtains Fast Track Status from FDA for Oral Laquinimod.....II-21
Genzyme Signs an Agreement with Bayer Healthcare.....II-21
EMD Serono to Set Up Research Facility in Massachusetts.....II-21
1$120
   EMD Serono Enters into a Partnership with Fast Forward.....II-22
Biogen Idec Secures US-FDA Approval for Production Process of TYSABRI®.....II-22
Biogen Idec Enters into a License Agreement with Acorda Therapeutics.....II-22
1$120
   Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated Interferon
  Beta-1a.....II-23
Bayer Schering Pharma Receives SFDA of China Approval for Betaferon®.....II-23
Merck Serono Signs an Agreement with Bionomics.....II-23
1$120
   Orasi Medical Establishes New Office in Tokyo.....II-24
Merck Serono and Ambrx to Extend Collaboration for Multiple Sclerosis.....II-24
Kineta Acquires Novel Therapeutic Compounds from Airmid.....II-24
1$120
   MediciNova Enters into Agreement with Avigen.....II-25
Biogen Idec Takes Over Facet Biotech.....II-25
Teva Pharmaceutical Industries to Take over CoGenesys.....II-25
Merck Serono Introduces RebiSmartTM Electronic Injection Device.....II-25
1$120
   Bayer to Launch Betaferon Titration Pack.....II-26
MediciNova Announces Phase II Clinical Trial Results of MN-166.....II-26
The Myelin Repair Foundation Signs Strategic Deal with Dalton Pharma Services.....II-26
Acorda Therapeutics Takes Over Neurorecovery.....II-26
1$120
   Bayer to Introduce 30-Gauge Needle for Betaferon®.....II-27
Biogen Idec Commences Late-Stage Trial of Oral Compound Bg-12.....II-27
Bayer Acquires Biologics Manufacturing Plant from Novartis.....II-27
1$120
   Bayer Schering Pharma AG (Germany).....II-28
Biogen Idec Inc. (US).....II-28
1$120
   Elan Pharmaceuticals, Inc. (US).....II-29
Genzyme Corp. (US).....II-29
Merck Serono SA (Switzerland).....II-29
1$120
   Novartis AG (Switzerland).....II-30
Sanofi-Aventis SA (France).....II-30
1$120
   Teva Pharmaceuticals Industries Limited (Israel).....II-311$120
   Table 4: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region - US, Japan, Europe and Rest of World - Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-321$350
   Table 5: World 10-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-331$350
   Table 6: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Leading Drugs - Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-341$350
   Table 7: World 10-year Perspective for Multiple Sclerosis Therapeutics by Leading Drugs - Percentage Breakdown of Dollar Sales for Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-351$350
   A. Market Analysis.....III-1
Overview.....III-1
Table 8: US Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-1
1$200
   Strategic Corporate Developments.....III-25$175
   Key Players.....III-7
Biogen Idec, Inc......III-7
1$75
   Elan Pharmaceuticals, Inc......III-8
EMD Serono, Inc......III-8
Genzyme Corp......III-8
1$75
   B. Market Analytics.....III-9
Table 9: US Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-9
1$200
   A. Market Analysis.....III-10
Overview.....III-10
Table 10: Japanese Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-10
Strategic Corporate Development.....III-10
1$200
   B. Market Analytics.....III-11
Table 11: Japanese Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-11
1$200
   A. Market Analysis.....III-12
Overview.....III-12
Table 12: Multiple Sclerosis Prevalence in Select European Countries for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-12
1$200
   Low Penetration to Fuel Growth in European MS DMDs Market.....III-13
Oral Medication for MS in Near Future.....III-13
Strategic Corporate Development.....III-13
1$75
   Key Players.....III-14
Bayer Schering Pharma AG (Germany).....III-14
Merck Serono SA (Switzerland).....III-14
1$75
   Novartis AG (Switzerland).....III-15
Sanofi-Aventis SA (France).....III-15
1$75
   B. Market Analytics.....III-16
Table 13: European Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-16
1$200
   A. Market Analysis.....III-17
Overview.....III-17
Increasing Incidence of Multiple Sclerosis in Canada.....III-17
Strategic Corporate Developments.....III-17
1$75
   Key Player.....III-18
Teva Pharmaceuticals Industries Limited (Israel).....III-18
1$75
   B. Market Analytics.....III-19
Table 14: Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-19
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com